Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulevostinag + Pembrolizumab in first-line metastatic HNSCC
NCT04220866Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2020
- Primary completion
- Sep 2022
- Modality
- Modified DNA Aptamers, Vaccines & Immunotherapeutics, Spiegelmers
- Countries
- 10
01
Overview
A Phase 2 trial of Ulevostinag in head and neck squamous cell carcinoma (HNSCC), sponsored by Merck & Co.. Started Mar 2020; status: completed.
02
Drugs
Ulevostinag
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04220866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220866.